Bicos

Quick links to important sections

Bicos

Method of action: Antifungal Broad Spectrum

Treatment option: Hyperhidrosis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bicos

What is Bicos? Defining the Topical Antifungal

Property Description
Active Ingredient Bifonazole
Form Cream, Solution, Gel, Powder
Pharmacological Class Azole Antifungal, Antimycotic
Typical Use Management of fungal proliferation on skin
Origin Synthetic Drug (Imidazole Derivative)

Bicos is a topical antifungal medicine whose sole active ingredient is Bifonazole, designed specifically for dermal application to manage fungal proliferation. The medicine is fundamentally classified as an antimycotic belonging to the azole pharmacological class, which identifies its core function and chemical family. The active ingredient is an antifungal agent effective against a broad spectrum of fungi.


What Type of Medicine is Bicos? (Identity and Classification)

Bicos is a single-component product distinguished by its synthetic nature, as its therapeutic agent, Bifonazole, is a chemically synthesized imidazole derivative. This classification within the azole pharmacological class immediately defines its therapeutic mission as targeting various forms of fungal organisms. The product is intended for activity against key dermatophytes and yeasts.


Understanding the Origin and Form of Bifonazole (Composition and Physical Type)

The active ingredient, Bifonazole, is confirmed to be a synthetic drug and is not naturally sourced. Bicos is prepared in multiple high-level dosage forms, including a cream, solution, gel, and powder, ensuring adaptability for different skin conditions and body areas. This range of forms allows for targeted application, such as using the solution for hard-to-reach areas or the cream for drier skin surfaces, a differentiating feature of Bifonazole preparations.


What is the General Purpose of Bicos? (Core Therapeutic Action)

The general therapeutic purpose of Bicos is to achieve the effective elimination or control of fungal microorganisms on the skin, a necessary action in a typical use scenario involving superficial skin infections. This is accomplished because Bifonazole possesses a notable dual mechanism of action against fungal cells. This action aims to disrupt the fungal cell structure, providing both a fungistatic effect (halting growth) and a fungicidal effect (actively destroying the cells). This comprehensive disruption defines the medicine's commitment to resolving mycotic conditions.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Bicos?

Possible Side Effects and Safety Information

The official regulatory documentation for Bicos, which contains Bifonazole, defines its safety profile primarily through adverse reactions classified by frequency and the body system affected. The most common adverse effects are localized, generally transient, and fall under Skin and Subcutaneous Tissue Disorders.

Adverse reactions are classified based on the frequency documented in clinical trials and post-marketing surveillance:

Frequency Classification Examples of Adverse Reactions (Label Terminology)
Common (up to 1 in 10) Pruritus, burning sensation, skin irritation, contact dermatitis
Uncommon (up to 1 in 100) Eczema, skin oedema, pain at application site, skin exfoliation
Not Known Hypersensitivity reactions

The most frequent local reactions, such as pruritus and burning sensation, are often reported at the start of treatment and are typically transient. Although rare, the potential for Hypersensitivity Reactions is listed within the official safety documentation, categorized under Immune System Disorders.

High-Level Safety Constraints

The medicine is contraindicated for patients with a known hypersensitivity to Bifonazole or to any of the product's excipients. Regulatory documentation states specific constraints for certain populations and concomitant use:

  • Pregnancy: Use of Bicos should be avoided during the first trimester.
  • Concomitant Medication: A specific safety note exists regarding oral warfarin. Due to the potential for a high-level consequence (increased International Normalised Ratio or INR), appropriate monitoring is required when Bicos is used simultaneously with oral warfarin.

This structure ensures the medicine's risk profile is clearly defined by localized skin effects and specific high-level regulatory restrictions.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation establishes that Bicos, containing topical Bifonazole, presents no risk of acute intoxication and is formally classified as unlikely to occur following either a single application over a large dermal area or inadvertent oral ingestion.

Documented Overdose Scenario and Clinical Manifestations

The officially documented scenario for potential overdose symptoms relates to accidental oral ingestion. Should this occur and clinical symptoms become apparent, they are formally listed as dizziness, nausea, and vomiting. No specific population-based considerations regarding increased overdose severity for children, the elderly, or those with impaired organ function are detailed in the official overdose section.

Emergency Actions and Supportive Measures

Regulators state that if an overdose is suspected, users must seek immediate medical advice or contact a physician immediately. For accidental swallowing, this may involve contacting a Poisons Information Centre or an Accident and Emergency Department. There is no specific antidote documented in the prescribing information. Supportive measures, such as gastric lavage, are explicitly conditional: they should be performed only if symptoms are present and only if the treating medical professional can ensure that airway protection is adequately provided.

Therapeutic Uses of Bicos

What Bicos Treats: Main Uses and Benefits

Bicos, which contains the active ingredient Bifonazole, is a topical medicine used in dermatology to address superficial fungal infections and the symptoms related to irritative states on the skin. Its therapeutic applications are used for managing the infectious cause while providing supportive symptom management. The medicine is intended for the treatment of fungal skin infections caused by dermatophytes, yeasts, moulds, and other fungi.


Treatment Focus and Symptom Relief

Bicos is commonly used for managing the fungal agent in conditions such as Tinea Pedis (Athlete's foot), Tinea Cruris (Jock itch), Tinea Corporis (Ringworm), and Cutaneous Candidiasis. This approach is relevant in conditions involving inflammatory or irritative processes caused by the infection. The medicine is applied in addressing symptom clusters that may become intense or disruptive, helping to ease manifestations like intense pruritus (itching), the burning sensation, and skin redness (erythema), and is relevant for easing visible symptoms related to skin integrity, such as scaling and peeling. By managing these symptoms, Bicos is designed to assist with day-to-day comfort during symptomatic periods.

“This symptomatic support assists with maintaining functional stability and helps patients cope more steadily during difficult episodes of skin mycosis.”

Quick Fact: Relief for Irritation and Burning Bicos is commonly used to help with pruritus and burning sensation associated with acute, localized fungal outbreaks, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bicos? (Official Eligibility Rules)

Eligibility for Bicos (Bifonazole topical) is strictly defined by government regulatory documents, outlining populations for whom use is permitted, restricted, or contraindicated. This information is non-advisory and reflects official labeling.

Contraindicated Populations (Must Not Use)

Use of Bicos is absolutely contraindicated if there is a known hypersensitivity to the active ingredient, bifonazole, or to other related imidazole antifungal agents.

Age-Related Eligibility and Restrictions

Age Group Regulatory Status
Adults / Adolescents Standard use is generally established.
Infants / Toddlers Must only be used under medical supervision.
Infants (Nappy Rash) Contraindicated (Must not be used).

Use Restrictions for Special Populations

Bicos is not normally recommended for use by pregnant women, especially during the first trimester. Use is conditional on a physician's assessment of benefit versus risk to the fetus. It should not be used by nursing mothers due to unknown excretion into breast milk, and it must not be applied to the chest area during lactation.

Additionally, the product is prohibited from use in the eyes (ophthalmic use) and on mucosal membranes. Patients taking warfarin require appropriate monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies a specific pharmacokinetic interaction pattern for topical Bifonazole (Bicos). This pattern is rooted in the medicine's potential to act as an inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme.


Documented Pharmacokinetic Interaction

Interaction Type Interacting Medicines Official Outcome
Enzyme Inhibition Oral Anticoagulants (e.g., Warfarin) Increased plasma concentration of the anticoagulant, observed as a rise in INR (International Normalized Ratio).

Interaction-Related Restrictions

No formal drug combinations are universally documented as contraindicated for the topical formulation. Similarly, regulatory labels do not prescribe mandatory timing separation requirements with other medicines, food, or supplements.

However, due to the documented potential for reduced clearance of co-administered oral anticoagulants, official guidance requires close monitoring of the patient's coagulation status (INR) when Bicos is used simultaneously. This constraint is particularly relevant when Bicos is applied over large skin areas, under occlusion, or to damaged skin, which could potentially increase systemic absorption. This monitoring requirement is the primary constraint defining the official interaction profile.

Mechanism of Action

How Bicos Works: Pharmacodynamic Mechanism

Bicos (Bifonazole) works through a unique dual-acting mechanism that targets the core biological processes necessary for fungal survival and replication.


Dual-Point Inhibition of Fungal Cell Structure

This domain covers Bifonazole's inhibitory action against the ergosterol biosynthesis pathway, which is essential for fungal cell membrane synthesis. The molecule acts as an inhibitor on two crucial enzymes: Lanosterol 14-alpha-demethylase (CYP51A1) and HMG-CoA reductase. This dual-point blockade results in the accumulation of toxic molecular intermediates and a concomitant depletion of essential ergosterol.


Achieving Fungicidal and Fungistatic Effects

The molecular cascade initiated by the dual enzyme inhibition leads directly to the primary physiological outcomes. The profound disruption and structural failure of the fungal cell membrane result in a fungicidal effect (active destruction and cell lysis). Separately, the structural impairment and accumulation of toxic sterols also lead to a fungistatic effect (arrested fungal growth and replication).


Modulation of Local Tissue Responses

Bifonazole's mechanism includes a secondary modulatory effect on localized physiological responses. This mechanistic consequence involves a reduction of inflammatory signaling factors, such as Prostaglandin E2 (PGE2), at the site of biological activity.

Dosage and Administration Information

Bicos is administered exclusively via the topical dermal route, strictly for external use on the skin. The medicine is typically available in a standard 1% concentration across multiple forms, including cream, solution, gel, and powder. The essential pattern for using Bicos involves a uniform, non-systemic approach, applying the preparation to the entire affected area and surrounding skin.

The dosing frequency for Bifonazole is once daily (QD), typically for application in the evening before bedtime to maximize contact time. Before application, the standard procedure involves the affected area being cleaned and thoroughly dried to ensure effective adherence. A thin layer or small amount is applied, which is then lightly rubbed in, followed by washing hands.

The duration of the treatment course is defined by the specific fungal condition being addressed. For example, treatment for Tinea Pedis involves a course of approximately three weeks, while cutaneous candidiasis generally involves approximately two weeks. This duration is intended to be completed regardless of initial symptom resolution. No dose adjustments are noted for older adults or individuals with renal or hepatic impairment, a pattern established by the drug's negligible systemic absorption. If an application is missed, the standard procedure is to apply the treatment as soon as it is remembered and then resume the usual once-daily schedule.

Recent Clinical Evidence

Bicos, containing the active ingredient bifonazole, has been evaluated in clinical studies, primarily Randomized Controlled Trials (RCTs) and comparative trials against placebo or other topical antifungals. This research provides context on group patterns, but it does not determine how an individual will respond to the medicine.

Evidence for use in Treating Dermatophytoses (Athlete's Foot and Ringworm)

For common fungal infections like Tinea Pedis and Ringworm, research has explored the patterns of change in symptoms and the presence of fungi over defined time intervals. Studies focused on adults and monitored Mycological Cure (clearance of organisms) and Clinical Cure (status of visible signs and perceived discomfort). Findings describe patterns observed in the studies related to the measured change in physical discomfort. Post-treatment observation periods were frequently used to document the status of clearance following treatment. Long-term outcomes related to sustained clearance are not fully established beyond these follow-up periods.

Evidence for use in Treating Cutaneous Candidiasis and Pityriasis Versicolor

Research has also examined Bicos for specific yeast infections. For Cutaneous Candidiasis and Pityriasis Versicolor, studies examined the status of yeast organisms and the clinical response in affected skin areas. The findings indicate patterns related to the measured status of causative organisms. The evidence base for these uses is primarily derived from a collection of individual clinical trials, and large, recent systematic reviews are not widely available.

Research Gaps and Limitations

The overall evidence base presents areas of uncertainty, particularly regarding long-term effects, which are not fully established. Data for certain patient groups, such as pediatric populations, remain limited in published summaries, meaning results apply mainly to the adult populations studied. Sample sizes in many older studies were modest, and comparative evidence against some newer topical antifungal agents is often lacking in current regulatory summaries.

Key Studies & References

  1. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: A systematic review
  2. Efficacy of Bifonazole and Clotrimazole in the Treatment of Pityriasis Versicolour (Randomised controlled trial)

Frequently Asked Questions (FAQ)

Common questions about Bicos (FAQ)

Q: How long does it take for Bicos to start working?

Clinical trial research has focused on measured outcomes like Mycological Cure (clearance of the fungus) and Clinical Cure (symptom status) over the full course of therapy, which generally lasts between two and three weeks depending on the condition. The official product information specifies the full treatment duration required for the intended therapeutic outcome.


Q: Is it normal to feel [General feeling, e.g., tired/a little dizzy] when taking Bicos?

Official reports state that the most frequent adverse reactions are localized skin reactions at the application site, such as a burning sensation or itching. Due to the negligible systemic absorption of topical Bicos (Bifonazole), systemic effects like tiredness or dizziness are not commonly documented in the adverse reaction profile.


Q: What are the most commonly reported side effects of Bicos?

According to official regulatory documents, the most commonly reported adverse effects are localized reactions affecting the skin. Official reports describe these as pruritus (itching) and a burning sensation where the medicine is applied. These local effects are often transient and may be most noticeable at the start of treatment.


Q: Can Bicos be taken safely with vitamins or herbal supplements?

Official regulatory labels do not prescribe mandatory timing separation requirements with most non-medicine products, including food, vitamins, or herbal supplements. The primary documented interaction involves specific oral anticoagulants, which is a consideration for systemic effects, but the topical formulation has minimal systemic absorption.


Q: Is it safe to drink coffee while taking Bicos?

There are no mandatory separation requirements prescribed in official regulatory labels regarding the timing of Bicos application and the consumption of food or common beverages like coffee. The official guidance focuses on the potential interaction with oral anticoagulants rather than dietary restrictions.


Q: Is Bicos safe to use long-term?

The prescribed duration of use for Bicos is specifically defined by the fungal condition being treated, typically requiring a course of two to three weeks. Official documentation notes that the evidence base suggests areas of uncertainty regarding the potential long-term effects, as data is not fully established beyond the standard follow-up periods of clinical studies.


Q: Is Bicos safe during pregnancy or breastfeeding (descriptive question)?

Official regulatory documents indicate that Bicos should be avoided during the first trimester of pregnancy. Furthermore, it is unknown whether the active ingredient, Bifonazole, passes into human breast milk, and its use is not recommended for nursing mothers.


Q: Can Bicos be crushed or split to make it easier to swallow?

Bicos is administered exclusively via the topical dermal route, meaning it is strictly for external use on the skin. It is available in forms like a cream, solution, or gel, and it is not intended for oral ingestion, crushing, or swallowing.


Q: If I miss a day of Bicos, does it ruin the whole treatment effect?

The full course of treatment must be completed regardless of initial symptom resolution to ensure the entire fungal infection is cleared. The standard regulatory procedure for a missed application describes resuming the usual once-daily schedule after the treatment is applied as soon as it is remembered.


Q: Does Bicos interact with common pain relievers like Tylenol or Advil?

The only specific pharmacokinetic interaction pattern officially documented is with oral anticoagulants (e.g., Warfarin), where coagulation status must be closely monitored. No specific interaction is documented in official regulatory documents with common non-prescription pain relievers.


Q: Do you need a special diet while taking Bicos?

Official regulatory labels do not prescribe mandatory separation requirements with food or other products. Therefore, there is no official guidance recommending that individuals follow a special diet while using Bicos.


Q: What kind of research has been done on the long-term effects of Bicos?

Clinical studies have examined the status of clearance and symptoms over defined treatment periods. However, regulatory summaries indicate that the evidence base suggests areas of uncertainty regarding long-term effects, which are not fully established beyond these defined follow-up periods.


Q: Can Bicos cause changes in mood or sleep patterns?

The medicine is for external application on the skin and has negligible systemic absorption, meaning very little of the active ingredient enters the body’s system. Therefore, Bicos is not commonly associated with systemic effects like changes in mood or sleep patterns in its documented adverse reaction profile.


Q: What should I do if Bicos makes my stomach upset?

Bicos is strictly for topical application on the skin, and upset stomach is not a listed side effect of topical use. Official labels note that accidental ingestion (swallowing) of the medicine is an event that should be promptly addressed.


Q: Why is Bicos sometimes taken at night versus in the morning?

The official dosing frequency for Bicos is once daily (QD). Official product information suggests application in the evening before bedtime. This timing is described as optimizing the contact time of the preparation with the affected skin area.


Q: Can you be allergic to Bicos, and what does an allergic reaction look like?

Bicos is contraindicated if a known hypersensitivity to the active ingredient, Bifonazole, or to related antifungal agents exists. The potential for a severe allergic reaction (hypersensitivity) is described in official documentation. Symptoms may include rash, swelling of the face/throat/tongue, or breathing difficulties.


Q: Do I need to inform other specialists that I am taking Bicos?

Bicos has a documented potential to interact with certain oral anticoagulants (e.g., Warfarin), requiring close monitoring of the patient’s coagulation status. Due to this requirement, official guidance outlines the need for appropriate monitoring when Bicos is used simultaneously with oral anticoagulants.


Q: Does Bicos interfere with driving or operating machinery?

Official documentation states that Bicos has no known influence on the ability to drive or use machines.

How should Bicos be stored and disposed of?

How to Store and Dispose of Bicos (Bifonazole Topical)

Storage Requirements

Bicos must be stored according to regulatory specifications to maintain its stability. The product should be stored at temperatures not exceeding 30°C. It is mandatory to Keep out of the sight and reach of children. The medicine must remain in the manufacturer's original tube until it is ready for application. Do not use the product past the stated expiry date or if the color changes.

Disposal Instructions

Unused or expired Bicos must be disposed of responsibly. Do not dispose of this medicine in wastewater or household waste. All disposal must be carried out in accordance with local regulatory requirements, often through official drug take-back or collection programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bicos found in:

A-Z Index: